Our inventors have isolated secondary metabolites from mangrove endophytic fungi that target M. tuberculosis and inhibits its growth. Many of these metabolites have between 70% to even 92% inhibition at higher concentrations. They also have a large mammalian IC50, as well as a low minimum inhibitory concentration (MIC). These newly discovered compounds were also tested for human cytotoxicity, of which there was very little. This combination of M. tuberculosis inhibition and low cytotoxicity make these compounds great as treatments of TB, either to treat someone already showing symptoms. Or as a preventative method in case TB latency is suspected.
Chart Showing the Percent Inhibition of The Novel Metabolites on TB Related Species M. Abscessus